AnaptysBio authorizes up to $75M stock repurchase plan

ANAPTYSBIO, INC

Board authorized $75M buyback of outstanding common stock.
Company holds >$420M cash as of Dec 2024; expects $75M GSK milestone in 2025/2026.
Reiterates cash runway through year-end 2027, excluding potential GSK royalties.
Repurchases via open market under Rule 10b5-1; plan expires Dec 31, 2025.

item 8.01 item 9.01

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-25-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.